NO324249B1 - Glykopyranosyloksybenzylbenzenderivater, medisinske sammensetninger inneholdende slike, samt intermediater til fremstilling av derivatene - Google Patents

Glykopyranosyloksybenzylbenzenderivater, medisinske sammensetninger inneholdende slike, samt intermediater til fremstilling av derivatene

Info

Publication number
NO324249B1
NO324249B1 NO20024424A NO20024424A NO324249B1 NO 324249 B1 NO324249 B1 NO 324249B1 NO 20024424 A NO20024424 A NO 20024424A NO 20024424 A NO20024424 A NO 20024424A NO 324249 B1 NO324249 B1 NO 324249B1
Authority
NO
Norway
Prior art keywords
group
derivatives
hydroxy
intermediates
glycopyranosyloxybenzylbenzene
Prior art date
Application number
NO20024424A
Other languages
English (en)
Norwegian (no)
Other versions
NO20024424L (no
NO20024424D0 (no
Inventor
Toshihiro Nishimura
Kenji Katsuno
Masahiro Hiratochi
Nobuhiko Fushimi
Kazyua Tatani
Yoshiki Tokutake
Masayuki Isaji
Hideki Fujikura
Original Assignee
Kissei Pharmaceutical Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=18594892&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO324249(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kissei Pharmaceutical Company filed Critical Kissei Pharmaceutical Company
Publication of NO20024424D0 publication Critical patent/NO20024424D0/no
Publication of NO20024424L publication Critical patent/NO20024424L/no
Publication of NO324249B1 publication Critical patent/NO324249B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
NO20024424A 2000-03-17 2002-09-16 Glykopyranosyloksybenzylbenzenderivater, medisinske sammensetninger inneholdende slike, samt intermediater til fremstilling av derivatene NO324249B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000077304 2000-03-17
PCT/JP2001/002041 WO2001068660A1 (fr) 2000-03-17 2001-03-15 Derives glucopyranosyloxybenzylbenzene, preparations medicinales les contenant et intermediaires pour la preparation desdits derives

Publications (3)

Publication Number Publication Date
NO20024424D0 NO20024424D0 (no) 2002-09-16
NO20024424L NO20024424L (no) 2002-11-18
NO324249B1 true NO324249B1 (no) 2007-09-17

Family

ID=18594892

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20024424A NO324249B1 (no) 2000-03-17 2002-09-16 Glykopyranosyloksybenzylbenzenderivater, medisinske sammensetninger inneholdende slike, samt intermediater til fremstilling av derivatene

Country Status (28)

Country Link
US (3) US7465712B2 (xx)
EP (1) EP1270584B1 (xx)
JP (1) JP3773450B2 (xx)
KR (1) KR100660738B1 (xx)
CN (1) CN1177857C (xx)
AT (1) ATE312114T1 (xx)
AU (2) AU2001241146B8 (xx)
BG (1) BG65867B1 (xx)
BR (1) BR0109323A (xx)
CA (1) CA2402609C (xx)
CZ (1) CZ20023023A3 (xx)
DE (1) DE60115623T2 (xx)
DK (1) DK1270584T3 (xx)
ES (1) ES2254376T3 (xx)
HK (1) HK1055973A1 (xx)
HU (1) HUP0300057A3 (xx)
IL (2) IL151757A0 (xx)
MX (1) MXPA02009034A (xx)
NO (1) NO324249B1 (xx)
NZ (1) NZ521369A (xx)
PL (1) PL205605B1 (xx)
RU (1) RU2254340C2 (xx)
SK (1) SK287183B6 (xx)
TR (1) TR200202200T2 (xx)
TW (1) TWI293305B (xx)
UA (1) UA72586C2 (xx)
WO (1) WO2001068660A1 (xx)
ZA (1) ZA200207418B (xx)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1020944C (zh) 1990-01-30 1993-05-26 阿图尔-费希尔股份公司费希尔厂 紧固件
US6683056B2 (en) * 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
SK287811B6 (sk) 2000-09-29 2011-10-04 Kissei Pharmaceutical Co., Ltd Glukopyranozyloxybenzylbenzénový derivát, farmaceutická kompozícia a ľudský SGLT2-inhibítor tento derivát obsahujúci a použitie tohto derivátu
US7053060B2 (en) 2000-11-30 2006-05-30 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates in the production thereof
TWI255817B (en) * 2001-02-14 2006-06-01 Kissei Pharmaceutical Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof
JPWO2003011880A1 (ja) * 2001-07-31 2004-11-18 キッセイ薬品工業株式会社 グルコピラノシルオキシベンジルベンゼン誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
EP1489089A4 (en) * 2002-03-22 2009-10-28 Kissei Pharmaceutical CRYSTALS OF GLUCOPYRANOSYLOXYBENZYLBENZEN DERIVATE
US7956041B2 (en) 2002-04-26 2011-06-07 Ajinomoto Co., Inc. Prophylactic and therapeutic agent of diabetes mellitus
CN100341885C (zh) * 2002-08-09 2007-10-10 大正制药株式会社 选择性制备芳基5－硫代－β－D－吡喃己醛糖苷的方法
JP4651934B2 (ja) * 2002-12-04 2011-03-16 キッセイ薬品工業株式会社 ベンジルフェノール誘導体、それを含有する医薬組成物およびその医薬用途
DE10258007B4 (de) * 2002-12-12 2006-02-09 Sanofi-Aventis Deutschland Gmbh Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
DE10258008B4 (de) * 2002-12-12 2006-02-02 Sanofi-Aventis Deutschland Gmbh Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
LT2896397T (lt) * 2003-08-01 2017-11-27 Mitsubishi Tanabe Pharma Corporation Nauji junginiai, turintys inhibitorinį aktyvumą prieš nuo natrio priklausomą gliukozės transporterį
UA86042C2 (xx) * 2003-08-01 2009-03-25 Янссен Фармацевтика Н.В. Заміщені індазол-о-глюкозиди$замещенные индазол-о-глюкозиды
EA010422B1 (ru) 2003-08-01 2008-08-29 Янссен Фармацевтика Н.В. Замещённые индол-о-глюкозиды
EP1680414A4 (en) 2003-08-01 2009-05-27 Janssen Pharmaceutica Nv SUBSTITUTED INDAZOLE-O-GLUCOSIDE
US8785403B2 (en) 2003-08-01 2014-07-22 Mitsubishi Tanabe Pharma Corporation Glucopyranoside compound
US7094764B2 (en) 2003-08-01 2006-08-22 Janssen Pharmaceutica N.V. Substituted benzimidazole-, Benztriazole-, and benzimidazolone-O-glucosides
WO2005012318A2 (en) 2003-08-01 2005-02-10 Janssen Pharmaceutica Nv Substituted fused heterocyclic c-glycosides
US7375090B2 (en) 2003-08-26 2008-05-20 Boehringer Ingelheim International Gmbh Glucopyranosyloxy-pyrazoles, pharmaceutical compositions containing these compounds, the use thereof and processed for the preparation thereof
US7371732B2 (en) * 2003-12-22 2008-05-13 Boehringer Ingelheim International Gmbh Glucopyranosyloxy-substituted aromatic compounds, medicaments containing such compounds, their use and process for their manufacture
EP1730131B1 (de) * 2004-03-16 2012-05-09 Boehringer Ingelheim International GmbH Glucopyranosyl-substituierte benzol-derivate, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
JPWO2005095429A1 (ja) * 2004-03-31 2008-02-21 キッセイ薬品工業株式会社 フェノール誘導体、それを含有する医薬組成物及びその医薬用途
US20080045466A1 (en) 2004-07-21 2008-02-21 Kenji Katsuno Progression Inhibitor For Disease Attributed To Abnormal Accumulation Of Liver Fat
TW200606129A (en) * 2004-07-26 2006-02-16 Chugai Pharmaceutical Co Ltd Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same
EP1813611B1 (en) 2004-11-18 2014-10-01 Kissei Pharmaceutical Co., Ltd. 1-substituted-3- beta-d-glycopyranosylated nitrogenous hetero- cyclic compounds and medicines containing the same
TW200637869A (en) 2005-01-28 2006-11-01 Chugai Pharmaceutical Co Ltd The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
UA90290C2 (ru) * 2005-01-28 2010-04-26 Чугаи Сейяку Кабусики Кайся Производные спирокеталов и их применение в качестве лекарственного средства против диабета
JP5073948B2 (ja) * 2005-01-31 2012-11-14 田辺三菱製薬株式会社 医薬組成物
AR053329A1 (es) * 2005-01-31 2007-05-02 Tanabe Seiyaku Co Derivados de indol utiles como inhibidores de los transportadores de glucosa dependientes del sodio (sglt)
TWI365186B (en) 2005-01-31 2012-06-01 Mitsubishi Tanabe Pharma Corp Indole derivatives
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP2076503B1 (en) 2006-05-19 2013-07-17 Taisho Pharmaceutical Co., Ltd C-phenyl glycitol compound for the treatment of diabetes
DE102006028862A1 (de) 2006-06-23 2007-12-27 Merck Patent Gmbh 3-Amino-imidazo[1,2-a]pyridinderivate
EP2036901B1 (en) 2006-06-29 2013-05-01 Taisho Pharmaceutical Co., Ltd C-phenyl 1-thioglucitol compound
TWI432446B (zh) * 2006-07-27 2014-04-01 Chugai Pharmaceutical Co Ltd 稠環螺酮縮醇衍生物、及其做為糖尿病治療藥之使用
TWI403516B (zh) 2006-07-27 2013-08-01 Chugai Pharmaceutical Co Ltd To replace spirocyclic alcohol derivatives, and its use as a therapeutic agent for diabetes
TWI418556B (zh) * 2006-07-27 2013-12-11 Mitsubishi Tanabe Pharma Corp 吲哚衍生物
TW200817424A (en) * 2006-08-04 2008-04-16 Daiichi Sankyo Co Ltd Benzylphenyl glucopyranoside derivatives
TWI499414B (zh) 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法
AU2007307544A1 (en) 2006-10-13 2008-04-17 Chugai Seiyaku Kabushiki Kaisha Thioglucose spiroketal derivative and use thereof as therapeutic agent for diabetes
ES2397664T3 (es) 2006-12-04 2013-03-08 Janssen Pharmaceutica, N.V. Derivados de glucopiranósilo que contienen tienilo como antidiabéticos
UY30730A1 (es) * 2006-12-04 2008-07-03 Mitsubishi Tanabe Pharma Corp Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
US8101634B2 (en) 2006-12-06 2012-01-24 Glaxosmithkline Llc Bicyclic compounds and use as antidiabetics
AU2007332476A1 (en) 2006-12-14 2008-06-19 Taisho Pharmaceutical Co., Ltd. 1-phenyl 1-thio-D-glucitol derivative
DE102007008420A1 (de) 2007-02-21 2008-08-28 Merck Patent Gmbh Benzimidazolderivate
WO2008109591A1 (en) * 2007-03-08 2008-09-12 Lexicon Pharmaceuticals, Inc. Phlorizin analogs as inhibitors of sodium glucose co-transporter 2
TW200904454A (en) * 2007-03-22 2009-02-01 Bristol Myers Squibb Co Methods for treating obesity employing an SGLT2 inhibitor and compositions thereof
CA2694029C (en) 2007-07-26 2016-10-04 Lexicon Pharmaceuticals, Inc. Methods and compounds useful for the preparation of sodium glucose co-transporter 2 inhibitors
MY162628A (en) 2007-09-10 2017-06-30 Janssen Pharmaceutica Nv Process for the preparation of compounds useful as inhibitors of sglt
DE102007048716A1 (de) 2007-10-11 2009-04-23 Merck Patent Gmbh Imidazo[1,2-a]pyrimidinderivate
CL2008003653A1 (es) 2008-01-17 2010-03-05 Mitsubishi Tanabe Pharma Corp Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
WO2009096503A1 (ja) * 2008-01-31 2009-08-06 Daiichi Sankyo Company, Limited ベンジルフェニルグルコピラノシド誘導体
DE102008017590A1 (de) 2008-04-07 2009-10-08 Merck Patent Gmbh Glucopyranosidderivate
AR072511A1 (es) 2008-07-15 2010-09-01 Theracos Inc Derivados deuterados de bencilbenceno y metodos de uso. composicion farmaceutica.
MY155418A (en) * 2008-08-28 2015-10-15 Pfizer Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
US9056850B2 (en) 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
CN101445528B (zh) * 2008-12-25 2011-06-15 天津药物研究院 硫代葡萄糖衍生物、其制备方法和用途
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
CN102482250B (zh) 2009-07-10 2014-11-19 詹森药业有限公司 1-(β-D-吡喃葡糖基)-4-甲基-3-[5-(4-氟苯基)-2-噻吩基甲基]苯的结晶方法
DK2486029T3 (en) 2009-09-30 2015-08-24 Boehringer Ingelheim Int Methods of making of glucopyranosyl-substituted benzyl-benzene derivatives.
PT2488515T (pt) * 2009-10-14 2017-04-11 Janssen Pharmaceutica Nv Processo para a preparação de compostos úteis como inibidores de sglt2
US8163704B2 (en) 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
WO2011048148A2 (en) 2009-10-20 2011-04-28 Novartis Ag Glycoside derivative and uses thereof
EA021983B1 (ru) 2009-11-02 2015-10-30 Пфайзер Инк. Производные диоксабицикло[3.2.1]октан-2,3,4-триола
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
KR101931209B1 (ko) 2010-05-11 2018-12-20 얀센 파마슈티카 엔.브이. Sglt의 억제제로서 1-(베타-d-글루코피라노실)-2-티에닐-메틸벤젠 유도체를 포함하는 약학 제형
EP2688402B1 (en) 2011-03-23 2018-10-24 University of Utah Research Foundation Means for treating or preventing urological inflammation
ME02469B (me) 2011-04-13 2017-02-20 Janssen Pharmaceutica Nv Proces za pripremu jedinjenja koja su korisna kao inhibitori sglt2
US8614195B2 (en) 2011-04-14 2013-12-24 Novartis Ag Glycoside derivatives and uses thereof
AU2012241426A1 (en) 2011-04-14 2013-10-31 Novartis Ag Glycoside derivatives and uses thereof
TWI542596B (zh) 2011-05-09 2016-07-21 健生藥品公司 （２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體
US9192617B2 (en) 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
EP2774619B1 (de) 2013-03-04 2016-05-18 BioActive Food GmbH Zusammensetzung zur Behandlung von hyperglykämischen Erkrankungen
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
PT2981271T (pt) 2013-04-05 2019-02-19 Boehringer Ingelheim Int Utilizações terapêuticas de empagliflozina
CN105377266A (zh) 2013-04-18 2016-03-02 勃林格殷格翰国际有限公司 药物组合物、治疗方法及其用途
EP2944311A1 (de) 2014-05-16 2015-11-18 BioActive Food GmbH Kombination von biologisch aktiven Substanzen zur Behandlung von hyperglykämischen Erkrankungen
CN105939157B (zh) * 2015-03-03 2019-08-06 卡西欧计算机株式会社 电平变换电路以及投影装置
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
CN113980071B (zh) * 2021-11-26 2023-08-22 重庆大学 红景天苷衍生物及其应用
CN114933619B (zh) * 2022-05-18 2024-03-01 上海科利生物医药有限公司 一类硫代糖苷列净类似物及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2549476B1 (fr) * 1983-07-20 1986-04-25 Rech Ind Benzyl-phenyl-osides, procede de preparation et utilisation en therapeutique
DE3718638A1 (de) * 1987-06-04 1988-12-22 Thomae Gmbh Dr K Neue phenylethanolamine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DK1213296T3 (da) * 1999-08-31 2004-08-16 Kissei Pharmaceutical Glucopyranosyloxpyrazolderivater, lægemidler indeholdende samme samt mellemprodukter til fremstilling heraf
US6683056B2 (en) * 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method

Also Published As

Publication number Publication date
ES2254376T3 (es) 2006-06-16
MXPA02009034A (es) 2003-09-10
CN1418219A (zh) 2003-05-14
EP1270584A4 (en) 2003-04-09
AU2001241146B2 (en) 2006-06-29
TWI293305B (en) 2008-02-11
NO20024424L (no) 2002-11-18
AU4114601A (en) 2001-09-24
US20050080022A1 (en) 2005-04-14
CN1177857C (zh) 2004-12-01
BR0109323A (pt) 2002-12-24
CA2402609C (en) 2010-06-15
NO20024424D0 (no) 2002-09-16
DK1270584T3 (da) 2006-04-18
TR200202200T2 (tr) 2002-12-23
PL205605B1 (pl) 2010-05-31
IL151757A (en) 2009-02-11
US7045665B2 (en) 2006-05-16
CA2402609A1 (en) 2001-09-20
UA72586C2 (en) 2005-03-15
CZ20023023A3 (cs) 2003-04-16
EP1270584A1 (en) 2003-01-02
SK287183B6 (sk) 2010-02-08
IL151757A0 (en) 2003-04-10
ZA200207418B (en) 2003-09-16
AU2001241146B8 (en) 2006-07-27
US7465712B2 (en) 2008-12-16
WO2001068660A1 (fr) 2001-09-20
EP1270584B1 (en) 2005-12-07
US20040053855A1 (en) 2004-03-18
KR100660738B1 (ko) 2006-12-22
PL358002A1 (en) 2004-08-09
SK12972002A3 (sk) 2003-07-01
ATE312114T1 (de) 2005-12-15
HK1055973A1 (en) 2004-01-30
DE60115623D1 (de) 2006-01-12
BG65867B1 (bg) 2010-03-31
DE60115623T2 (de) 2006-07-06
NZ521369A (en) 2004-07-30
RU2002124873A (ru) 2004-01-10
HUP0300057A2 (en) 2003-05-28
KR20020086649A (ko) 2002-11-18
US20050075294A1 (en) 2005-04-07
RU2254340C2 (ru) 2005-06-20
HUP0300057A3 (en) 2003-09-29
JP3773450B2 (ja) 2006-05-10
BG107102A (bg) 2003-04-30

Similar Documents

Publication Publication Date Title
NO324249B1 (no) Glykopyranosyloksybenzylbenzenderivater, medisinske sammensetninger inneholdende slike, samt intermediater til fremstilling av derivatene
DK1213296T3 (da) Glucopyranosyloxpyrazolderivater, lægemidler indeholdende samme samt mellemprodukter til fremstilling heraf
MY129023A (en) Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containing the same
NO20051209L (no) Pyrazolderivater, medisinske sammensetninger inneholdende slike, medisinsk anvendelse derav samt intermediater for samme
TW200420542A (en) A compound having TGF β inhibition activity and a medicinal composition containing the same
HK1094425A1 (en) Substituted 2-aminotetralines for the preventive treatment of parkinson's disease
IL176546A0 (en) Imidazoline derivatives having cb1-antagonistic activity
EP1092435A4 (en) ANTIDIABETIC DRUGS
AU9233101A (en) 5-amidino-2-hydroxybenzenesulfonamide derivatives, pharmaceutical compositions containing the same and intermediates for their preparation
HUP0301561A2 (hu) Triazintrion-szulfoxidok alkalmazása kokcidiózis elleni készítmények elżállítására
DE60211686D1 (de) Pkb-3564-substanz mit die gefässneubildung hemmender wirkung
UA84737C2 (ru) Производные имидазолина с антагонистической активностью относительно cb1

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees